Neuroprotection of Memantine and Rosuvastatin

Neuroprotection of Memantine and Rosuvastatin is a phase 2/3, randomised interventional study registered as NCT07504198 by Tanta University, with a registry enrolment figure of 46 participants, started 2026-03 and due to reach its primary completion in 2027-04. Interventions recorded: Starch Placebo; Memantine; Rosuvastatin 20 Mg Oral Tablet. Conditions listed: Peripheral Nerve Disease. Primary outcome: The primary outcome is the percentage of patients with sensory neuropathy grade ≥ 2 according to National Cancer Institute Common Terminology Criteria for Adverse Events for grading of neuropathy from 1 to 5 based on severity.. Colorectal eligibility wording from the registry: "* Patients with histologically confirmed diagnosis of stage III or stage IV colorectal cancer". Sites: Egypt. No results are recorded here; the registry entry is the source.